Δημοσιεύσεις

Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.

Export 243 results:
Συντάκτης Τίτλος [ Τύπος(Desc)] Έτος
Φίλτρα: Συντάκτης is Karagiannis, Asterios  [Clear All Filters]
Journal Article
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Nonalcoholic fatty liver disease and severity of cardiovascular disease manifestations.. Angiology. 64(8), 572-5.
Tziomalos, K., Athyros V. G., Paschos P., & Karagiannis A. (2015).  Nonalcoholic fatty liver disease and statins.. Metabolism. 64(10), 1215-23.
Tziomalos, K., Athyros V. G., & Karagiannis A. (2012).  Non-alcoholic fatty liver disease in type 2 diabetes: pathogenesis and treatment options.. Curr Vasc Pharmacol. 10(2), 162-72.
Athyros, V. G., Katsiki N., & Karagiannis A. (2016).  Off target effects of statins shape total mortality?. J Drug Assess. 5(1), 4-5.
Tziomalos, K., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2008).  Omega-3 fatty acids: how can they be used in secondary prevention?. Curr Atheroscler Rep. 10(6), 510-7.
Karagiannis, A., Tziomalos K., Kakafika A., Harsoulis F., & Zamboulis C. (2004).  Paralysis as first manifestation of primary aldosteronism.. Nephrol Dial Transplant. 19(9), 2418-9.
Boutari, C., Stavropoulos K., Imprialos K., Doumas M., & Karagiannis A. (2016).  PATHWAY-2: spironolactone for resistant hypertension.. Lancet. 387(10026), 1371-1372.
Kakafika, A. I., Mikhailidis D. P., Wierzbicki A. S., Karagiannis A., & Athyros V. G. (2007).  PCI and stable coronary heart disease--COURAGE to change our minds?. Curr Vasc Pharmacol. 5(3), 173-4.
Katsiki, N., Athyros V. G., Karagiannis A., & Mikhailidis D. P. (2014).  Peripheral artery disease in patients with type 2 diabetes.. J Diabetes Complications. 28(6), 912.
Patoulias, D., Stavropoulos K., Imprialos K., Athyros V., Doumas M., & Karagiannis A. (2019).  Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. Curr Vasc Pharmacol.
Upadhyay, J., Polyzos S. A., Perakakis N., Thakkar B., Paschou S. A., Katsiki N., et al. (2018).  Pharmacotherapy of type 2 diabetes: An update.. Metabolism. 78, 13-42.
Karagiannis, A., Mikhailidis D. P., Athyros V. G., & Harsoulis F. (2007).  Pheochromocytoma: an update on genetics and management.. Endocr Relat Cancer. 14(4), 935-56.
Karagiannis, A., Tziomalos K., & Zamboulis C. (2004).  Plasma B-type natriuretic peptide is related to left ventricular mass in hypertensive patients.. Eur Heart J. 25(21), 1967.
Athyros, V. G., Kakafika A. I., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2009).  Pleiotropic effects of statins--clinical evidence.. Curr Pharm Des. 15(5), 479-89.
Katsiki, N., Doumas M., Athyros V. G., & Karagiannis A. (2014).  Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit.. Expert Rev Cardiovasc Ther. 12(3), 295-6.
Schoina, M., Loutradis C., Theodorakopoulou M., Dimitroulas T., Triantafillidou E., Doumas M., et al. (2020).  The presence of diabetes mellitus further impairs structural and functional capillary density in patients with chronic kidney disease.. Microcirculation. e12665.
Athyros, V. G., Katsiki N., & Karagiannis A. (2013).  Prevalence and clinical outcome of polyvascular atherosclerotic disease in patients undergoing coronary intervention.. Circ J. 77(5), 1348.
Athyros, V. G., Ganotakis E. S., Elisaf M. S., Liberopoulos E. N., Goudevenos I. A., & Karagiannis A. (2007).  Prevalence of vascular disease in metabolic syndrome using three proposed definitions.. Int J Cardiol. 117(2), 204-10.
Athyros, V. G., Katsiki N., Tziomalos K., & Karagiannis A. (2011).  Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?. Open Cardiovasc Med J. 5, 226-30.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Preventing macrovascular complications of diabetes: where do we stand with glycemic control?. Expert Opin Investig Drugs. 17(12), 1777-9.
Athyros, V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2010).  Preventing type 2 diabetes mellitus: room for residual risk reduction after lifestyle changes?. Curr Pharm Des. 16(34), 3939-847.
Stavropoulos, K., Imprialos K. P., Katsiki N., Petidis K., Kamparoudis A., Petras P., et al. (2018).  Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. J Clin Hypertens (Greenwich). 20(5), 942-948.
Kakafika, A. I., Athyros V. G., Tziomalos K., Karagiannis A., & Mikhailidis D. P. (2008).  Primary and secondary coronary heart disease prevention using statins: is targeting Adam or Eve equally effective?. Expert Opin Pharmacother. 9(9), 1437-40.
Patoulias, D., Papadopoulos C., Stavropoulos K., Zografou I., Doumas M., & Karagiannis A. (2020).  Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodium-glucose co-transporter-2 inhibitors.. J Clin Hypertens (Greenwich).
Tsaganos, T., Tseti I. K., Tziolos N., Soumelas G-S., Koupetori M., Pyrpasopoulou A., et al. (2017).  Randomized, controlled, multicentre clinical trial of the antipyretic effect of intravenous paracetamol in patients admitted to hospital with infection.. Br J Clin Pharmacol. 83(4), 742-750.

Σελίδες

Επικοινωνία

Τμήμα Ιατρικής, Πανεπιστημιούπολη ΑΠΘ, T.K. 54124, Θεσσαλονίκη
 

Συνδεθείτε

Το τμήμα Ιατρικής στα κοινωνικά δίκτυα.
Ακολουθήστε μας ή συνδεθείτε μαζί μας.

           

Σύνδεσμοι

 

Το πανεπιστήμιο

 
 

Προσωπικό & Φοιτητές